BJ-005

Primary objectives: To investigate the safety and tolerability of different doses of BJ-005 administered by intravenous infusion (IV) in adult patients with advanced solid tumors. To explore the maximum tolerated dose (MTD) and/or recommended dose (RP2D) of BJ-005 for Phase II clinical trials. Secondary objectives: To investigate the preliminary efficacy of BJ-005 in adult patients with advanced solid tumors. To investigate the PK characteristics of BJ-005 in adult patients with advanced solid tumors under IV administration. To investigate the immunogenicity of BJ-005 in adult patients with advanced solid tumors. To investigate the effect of BJ-005 dosing regimen on pharmacodynamic (PD) parameters, including but not limited to: total PD-L1 level, free TGF-β1 level, cytokines IL-1β, IL2, IL4, IL6, IL10, IL17, IFN-γ and TNF-α in blood samples.